From Paper to Practice: Annex 1 Has Reset Expectations

**Title: From Paper to Practice: Annex 1 Has Reset Expectations**

The pharmaceutical manufacturing landscape is undergoing a quiet but profound recalibration. Two years after the European Commission’s revised Annex 1 on the manufacture of sterile medicinal products came into full effect, the industry is moving beyond the initial scramble for compliance documentation. For contract development and manufacturing organizations (CDMOs) serving the U.S. market, the real test has arrived: regulators and customers are no longer satisfied with written policies alone. They are demanding demonstrable, real-time evidence that contamination control strategies are embedded in daily operations—and many CDMOs are still falling short.

The shift is most visible in the gap between documented intent and operational reality. In 2026, inspectors and pharmaceutical clients alike are scrutinizing the “how” behind a CDMO’s contamination control strategy (CCS). A binder full of risk assessments and standard operating procedures is no longer sufficient. Customers now expect to see continuous environmental monitoring data that is reviewed in near real-time, clear evidence of personnel behavior change in classified areas, and robust quality risk management applied to every batch. The most common shortfalls are not in the paper systems, but in the execution: inconsistent aseptic technique, inadequate barrier system maintenance, and a lack of integrated quality oversight that connects deviation trends to the CCS. For a CDMO, a single inspection observation in these areas can erode years of customer trust.

For the CDMO sector, this reset carries strategic implications. The cost of compliance has risen, but the cost of non-compliance—lost business, remediation cycles, and reputational damage—is far higher. Mid-tier CDMOs that lack the capital to invest in isolator technology, real-time monitoring systems, or robust quality culture training are finding themselves squeezed out of high-value sterile fill-finish contracts. Meanwhile, large pharmaceutical clients are increasingly conducting pre-audits that go beyond standard regulatory checklists, focusing on the maturity of a CDMO’s quality system rather than its mere existence. The message is clear: in 2026, success in the CDMO space depends not on how well you write a procedure, but on how consistently you live it. The organizations that close the gap between paper and practice will define the next generation of sterile manufacturing partnerships.

Industry Context

This intelligence report covers the cdmo sector in US.

Data Source

Source: Contract Pharma View original